ENG Pellets
Casea S
- User: Female
- Hormonal: Hormonal
-
Delivery type:
- Subdermal
-
Intended Duration:
- Long-Acting
- Development Stage: Phase I
- Developer(s)/researcher(s): GeSea Biosciences, FHI 360, Daré Biosciences, Theramex
Details
- API: Etonogestrel
- Target: Progesterone Receptor
-
Mechanism of Action:
- Ovulation Inhibition
- Cervical Mucus Changes
- Inactive Materials: Cholesterol, Phosphatidyl Choline
- Regimen: 1 Insertion/12-24 Months
- MPT: Potential MPT
- Promising Attributes: Casea S is anticipated to provide an intermediate duration of contraceptive efficacy, in between current injectables and current implants, while having the potential advantage of bioabsorbing in situ with no need for removal.
Product Status
Active Clinical Research
History
1989: Capronor, a LNG-loaded biodegradable implant, evaluated as a novel contraceptive method.
1996: Annuelle, a NET-loaded biodegradable implant, evaluated as a novel contraceptive method
2000-Present: Development of biodegradable subdermal drug delivery approaches ongoing in industry and academic settings
2024: FHI 360 launches Phase 1 trial of Casea S ENG-loaded BDI
2025: Daré Bioscience and Theramex have entered into a co-development and licensing agreement for the product.